Advertisement

Topics

Companies Related to "A Study of RO5045337 in Patients With Solid Tumors" [Most Relevant Company Matches] - Page: 3 RSS

13:37 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "A Study of RO5045337 in Patients With Solid Tumors" found in our extensive corporate database of over 50,000 company records.

Showing "Study RO5045337 Patients With Solid Tumors" Companies 51–75 of 4,700+

Relevant

EOS Surfaces, LLC

EOS Surfaces, LLC is a solid surface manufacturer, founded in 2005, which revolutionized the solid surface industry with the first 3cm surface, a change from most ½” solid surfaces that require additional labor costs and edge build up for proper installation. The product received the International Solid Surface Fabricators Association’s (ISSFA...


Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...


Jennerex Biotherapeutics, Inc.

Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, ...

GT Medical Technologies, Inc.

Driven to overcome the limitations of current treatments for recurrent brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with recurrent brain tumors. Extensive clinical expertise informed the d...

NovoCure

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Neogenix Oncology, Inc.

Neogenix Oncology is a development stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to ca...

Vitrolife AB (publ)

The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been ...

Nanospectra Biosciences, Inc.

Nanospectra Biosciences has an exclusive license to a new class of materials developed at Rice University, AuroShellâ„¢ microparticles (originally called nanoshells). While there are numerous therapeutic, diagnostic and industrial commercial opportunities, Nanospectra is focused on the development of a therapy broadly applicable to virtually all solid tumors, AuroLaseâ„¢ Cancer Therapy.

Medifocus Inc.

Medifocus owns a patented microwave focusing technology platform the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of hea...

NovoCure Limited

NovoCure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Germany, Switzerland, and Japan and a research center in Haifa, Israel. For additional information about the company, please ...

Medifocus, Inc.

Medifocus owns a patented microwave focusing technology platform the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of hea...

EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in ...

Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Metabolic Targeting, a powerful scientific approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than convention...

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression. ...

Inovio Biomedical

Inovio Biomedical Corporation (AMEX: INO) is a leader in cancer and other medical therapies using electroporation-enabled delivery of useful biopharmaceuticalsInovio Biomedical Corporation (AMEX: INO) is a late stage biomedical company developing novel therapies enabled by electroporation, with a focus on addressing critical unmet treatment needs in oncology. Clinical results validate its local ca...

Seattle Genetics Inc.

Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercial...

MetaStat, Inc.

MetaStat, Inc (OTCQB:MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where syst...

The New York Eye Cancer Center

Eye Cancer Center is the first online-based community dedicated to eye tumor patients. This site was developed to help patients around the world find much needed information and research on the various forms of ocular tumors and related eye diseases. This includes detailed descriptions, images and information about the diagnosis and treatments for each of these disorders.

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Targepeutics

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other diseases.Our lead compound, Glioblast-13, is currently nearing Phase I clinical trials for high-grade giloma (brain cancer), and is showing promise against other solid tumors.Glioblast-13 is a genetically engineered recombinant protien that specifically binds and destroys ca...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

Splash Pharmaceuticals

Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is...

Splash Pharmaceuticals, Inc.

Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is...

Eureka Therapeutics Inc.

Eureka Therapeutics Inc. is a privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing first-in-class T cell immunotherapies for hematological malignancies and solid tumors. Its core technology platforms center around the discovery and engineering of fully human antibodies against intracellular targets via th...


More From BioPortfolio on "A Study of RO5045337 in Patients With Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks